COMMUNIQUÉS West-GlobeNewswire

Glucose Health, Inc. (OTCID: GLUC) Appoints Consumer Products Industry Veteran John Duffy as Chief Executive Officer to Accelerate Growth, Elevate Brand Leadership, and Maximize Long-Term Shareholder Value
28/08/2026
Seasoned Consumer Packaged Goods Executive Brings More Than 20 Years of Senior Leadership at Coca-Cola Enterprises and The Coca-Cola Company to Lead Glucose Health's Next Phase of Strategic Expansion and Value Creation [...]
ENvue Medical, Inc. Announces 1-for-12 Reverse Stock Split
28/08/2026
TYLER, Texas, Aug. 28, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) ("ENvue" or the "Company"), a commercial-stage medical technology company, today announced that a reverse stock split of the Company’s [...]
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
28/08/2026
BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system [...]
Advocates to hold nationwide Day of Action for federal action to stop two-tier, American-style health care
28/08/2026
TORONTO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- On Tuesday, September 1, health coalitions and allies across Canada will hold information pickets, rallies, and other actions in a National Day of Action to amplify our calls [...]
Micron Biomedical Honored with Georgia Life Sciences' Prestigious Phoenix Award for Transformative Research
28/08/2026
An active CDC clinical trial of Micron’s rotavirus vaccine and Lancet-published research on Micron’s self-administered influenza vaccine, both conducted at Emory University, are highlighted in the recognition for [...]
Mobia Medical Announces Addition of Paired VNS to Updated AHA Stroke Guidelines
28/08/2026
AUSTIN, Texas, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced that [...]
XORTX Announces Termination and Postponement of Investor Relations Program
28/08/2026
CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing [...]
Avricore Grants Options
28/08/2026
VANCOUVER, British Columbia, Aug. 28, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) today announces that the Company’s board of directors has approved the granting of stock options (the “Options”) [...]
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
28/08/2026
BXCL501, a novel dexmedetomidine sublingual film, is under FDA review for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. [...]
Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
28/08/2026
Interim Analysis of the First Six Patients to Complete 12 Weeks of Treatment Met Pre-Specified Alpha Adjusted Target for Primary Endpoint with Statistical Significance Four of Six (66.7%) Participants Achieved the [...]
BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals
28/08/2026
BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 [...]
Immuron Reports FY26 Preliminary Results
28/08/2026
MELBOURNE, Australia, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to release its preliminary results for financial year ending 30 June 2026. Results exceed expectations In [...]
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million
28/08/2026
ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today [...]
Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine
28/08/2026
ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM Supplemental New [...]
CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio
28/08/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 28, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that new solid forms and alternative crystal structures of its [...]
Chiesi Global Rare Diseases Demonstrates Its Ongoing Commitment to the Rare Disease Community at the Society of Inborn Errors of Metabolism (SSIEM) 2026 Annual Symposium
28/08/2026
-- Chiesi’s abstract presentations highlight clinical insights and patient-reported outcomes in Fabry disease and alpha-mannosidosis -- -- Rooted in patient voice and scientific rigor, this research reflects Chiesi’s [...]
Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD)
28/08/2026
The SALWEEN study showed significant improvements in vision and retinal health 1 More than 60% of Asian patients with polypoidal choroidal vasculopathy (PCV), an aggressive subtype of nAMD, treated with Vabysmo showed [...]
Chiesi Global Rare Diseases Demonstrates Its Ongoing Commitment to the Rare Disease Community at the Society of Inborn Errors of Metabolism (SSIEM) 2026 Annual Symposium
28/08/2026
-- Chiesi’s abstract presentations highlight clinical insights and patient-reported outcomes in Fabry disease and alpha-mannosidosis -- -- Rooted in patient voice and scientific rigor, this research reflects Chiesi’s [...]
Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half
28/08/2026
FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting Appropriate [...]

Pages